Challenges of modeling pristane-induced lupus in non-human primates

Abstract

A lupus-like condition induced by intraperitoneal administration of pristane (2,6,10,14-tetramethylpentadecane) in mice is widely used as a model of systemic lupus erythematosus (SLE). Due to their phylogenetic distance from humans, murine models are not always suitable tool for studying the specific activity of therapeutic agents and the pathogenesis of SLE. In order to overcome species-specific limitations of murine models, this approach was tested in non-human primates—cynomolgus monkeys (Macaca fascicularis). Two intraperitoneal injections at a dose of 3.5 mL/kg, administered at weeks 1 and 23, recapitulated SLE features, including: production of antinuclear autoantibodies (ANA), membranoproliferative glomerulonephritis with immune complex (IC) deposition in the glomeruli. However, from week 27 five of eight pristane-treated monkeys developed progressive respiratory failure. Two of these died at week 28 and the remaining were euthanized at week 32. The histology of the monkey lungs suggested exogenous lipoid pneumonia. Thus, while pristane induced serological autoimmunity and characteristic renal manifestations in Macaca fascicularis, the consequent lipoid pneumonia limited the observation period and prevented comprehensive evaluation of SLE manifestations beyond 32 weeks.

Keywords

exogenous lipoid pneumonia / experimental animal models / Macaca fascicularis / systemic lupus erythematosus

References

[1] Katarzyna PB, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatol Int. 2023; 43(8): 1395-1407.

[2] Accapezzato D, Caccavale R, Paroli MP, et al. Advances in the pathogenesis and treatment of systemic lupus erythematosus. Int J Mol Sci. 2023; 24(7):6578.

[3] Liu T, Neuner R, Thompson A, et al. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: a regulatory perspective. Lupus. 2022; 31(4): 424-432.

[4] Burki TK. FDA approval for anifrolumab in patients with lupus. Lancet Rheumatol. 2021; 3(10):e689.

[5] Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377(9767): 721-731.

[6] Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis. 2020; 79(10): 1340-1348.

[7] Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011; 63(12): 3918-3930.

[8] Li W, Titov AA, Morel L. An update on lupus animal models. Curr Opin Rheumatol. 2017; 29(5): 434-441.

[9] Xin Y, Zhang B, Zhao J, Liu Q, Yin H, Lu Q. Animal models of systemic lupus erythematosus and their applications in drug discovery. Expert Opin Drug Discov. 2022; 17(5): 489-500.

[10] Nacionales DC, Kelly KM, Lee PY, et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol. 2006; 168(4): 1227-1240.

[11] Pannu N, Bhatnagar A. Oxidative stress and immune complexes: pathogenic mechanisms in pristane induced murine model of lupus. Immunobiology. 2020; 225(1):151871.

[12] Lin J, Zhang Y, Wang M, et al. Therapeutic effects of tofacitinib on pristane-induced murine lupus. Arch Rheumatol. 2022; 37(2): 195-204.

[13] Chowdhary VR, Grande JP, Luthra HS, David CS. Characterization of haemorrhagic pulmonary capillaritis: another manifestation of pristane-induced lupus. Rheumatology (Oxford). 2007; 46(9): 1405-1410.

[14] Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 2009; 30(9): 455-464.

[15] Lee PY, Weinstein JS, Nacionales DC, et al. A novel type I IFN-producing cell subset in murine lupus. J Immunol. 2008; 180(7): 5101-5108.

[16] Lee PY, Kumagai Y, Li Y, et al. TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. J Exp Med. 2008; 205(13): 2995-3006.

[17] Wang J, Shen H, Zhu Y, et al. Characterization of a PRISTANE-induced lupus-associated model in the non-human primate cynomolgus monkey. J Med Primatol. 2018; 47(1): 18-28.

[18] Aringer M, Costenbader K, Daikh D, et al. European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019; 71(9): 1400-1412.

[19] Calvani N, Caricchio R, Tucci M, et al. Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. J Immunol. 2005; 175(7): 4777-4782.

[20] Yang F, He Y, Zhai Z, Sun E. Programmed cell death pathways in the pathogenesis of systemic lupus erythematosus. J Immunol Res. 2019; 2019:3638562.

[21] Satoh M, Kumar A, Kanwar YS, Reeves WH. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA. 1995; 92(24): 10934-10938.

RIGHTS & PERMISSIONS

2026 JSC BIOCAD. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.